Federally Funded Clinical Trials

Federally Funded Clinical Trials

Our research sites continue to participate in Federally-funded research through NRG Oncology.  The following protocols are currently open to accrual.  Please visit the NRG Oncology website or the CTSU members' website for more information.

NSABP B-51

Protocol Activation (Date Opened to Accrual): 08/22/2013

A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy

ClinicalTrials.gov Identifier: NCT01872975

 

 NRG - BR003

Protocol Activation (Date Opened to Accrual): 06/26/2015

A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

ClinicalTrials.gov Identifier: NCT02488967


NRG - BR004

Protocol Activation (Date Opened to Accrual): 03/12/2019

A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer

ClinicalTrials.gov Identifier: NCT03199885


NRG - BR005

Protocol Activation (Date Opened to Accrual): 04/13/2017

A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients With Clinical/Radiologic Complete Response After Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment Without Surgery

ClinicalTrials.gov Identifier: NCT03188393

NRG - GI002

Protocol Activation (Date Opened to Accrual): 10/12/2016

A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer

ClinicalTrials.gov Identifier: NCT02921256


NRG - GI004

Protocol Activation (Date Opened to Accrual): 11/7/17

Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer

ClinicalTrials.gov Identifier: NCT02997228